Sunday 18 October 2026
Export TTRX’s income statement to Excel — free account
Turn Therapeutics Inc.
TTRX Healthcare Biotechnology
In the quarter to June 2026, EPS fell 343.5% and free cash flow fell 74.8%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
10.57
1.02
−8.80%
Follow TTRX
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
| (3,315.33%) | 0.00% | 0.00% | 0.00% |
+4 more TTM periods Free account |
|
| (99.59%) | (41.16%) | (52.52%) | (192.64%) | ||
ROIC |
0.00% | (502.20%) | 0.00% | 0.00% | |
Return on Tangible Assets |
(507.53%) | (60.68%) | 395.79% | (420.08%) | |
Free Cash Flow per Share |
(0.15) | (0.14) | (0.10) | (0.07) | |
Free Cash Flow |
(4.46) | (4.06) | (2.72) | (2.03) | |
Capital Expenditures |
(0.14) | (0.17) | (0.15) | (0.21) | |
| Other line items | |||||
Cash ROIC |
(26.18%) | (17.46%) | (27.82%) | (56.23%) | |
Accounts Payable Turnover |
0.00 | — | — | — | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.51 | 1.02 | 0.80 | 0.44 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex/Depreciation |
(0.08) | (0.16) | (0.28) | (4.18) | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.15) | (0.13) | (0.09) | (0.06) | |
Capex per Share |
0.00 | (0.01) | (0.01) | (0.01) | |
Capex to Sales |
0.00 | 0.00 | 0.00 | 0.00 |
Columns are period end dates